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Immunotherapy has become one of the most profound
advances in the treatment of solid tumors. Unlike the
prior targeted therapies such as kinase inhibitors, there
are no clear mutations or definitive biomarkers of which
patients are likely to respond. It is well documented that
many patients with PDL1 negative tumors can still have
profound responses to PD1 inhibitors. As such there is
a critical need for predictors of response to these new
therapeutics. We hypothesize that patient tumor growth
kinetics correlate with endogenous ability to suppress
tumor growth and will predict overall benefit from
checkpoint inhibitors.
To establish this correlation, a retrospective study was
done that reviewed chest CTs from five patients with an
iRECIST of partial response and five non-responders
with an iRECIST of progressive disease. The ten patients
selected completed an ipilimumab treatment regimen
and had sufficient diagnostic imaging that dated back at
least 18 months prior to the start of their immunother-
apy treatment. The growth curves (pre-treatment) of
three lesions were obtained for each patient and then
averaged. The tumor growth kinetics were followed over
four time points (+/- 2 months) starting with 18 months
prior to immunotherapy treatment and ending at 2
months prior to treatment. Slopes of the obtained
curves were done on a linear scale.
A total of 10 patients were evaluated. The median age
was 54, the average number of prior treatments was 3,
and the tumor types varied, including melanoma, non-
small cell, colorectal, and anaplastic thyroid. We found
that the linear slope of the growth kinetics for the
responder patients was 0.3427 and the slope of the tumor
Figure 1 Tumor kinetics of responders vs. non-responders as a function of time.
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growth kinetics for the non-responder patients was
2.0821 (Figure 1). The p-value according to the student’s
t-test between the two slopes was 0.15.
There is great enthusiasm for the integration of check-
point inhibitors in solid tumors. Unfortunately the
majority of patients do not respond. Presently there are
no approved biomarkers to predict which patients are
most likely to benefit from immunotherapeutics. We
evaluated tumor growth kinetics prior to the initiation
of treatment and found that this is a simple way to
obtain prognostic information about the potential bene-
fit from immunotherapies. Tumor growth kinetics likely
reflect the biology of a tumor-host interaction; further
work needs to be done to validate these results and
potential biology in retrospective and prospective
studies.
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